2.290

+0.030 (+1.33%)
价格区间 2.270 - 2.470   (8.81%)
开盘 2.440
昨收 2.260
2.320
买盘 18
2.330
卖盘 10
成交量 8,494,371
成交额 -
注释
测量类型 成交额
EPS (USD) -0.266
Trailing EPS (USD) -0.341
NAV (USD) 0.295
Cash In Hand (USD) 0.29
Dividend -
Dividend Yield (%) -
PE -
Trailing PE -
Price / NAV 8.079
Price / Cash In Hand 8.221
Issued & Paid-up Shares 63,343,600
Treasury Shares 334
Market Cap (M) 150.758
Par Value (USD) n.a.
Beta - 75 Days 1.612
R-Squared - 75 Days(%) 0.18
Beta - 500 Days 0.369
R-Squared - 500 Days(%) 0.61
ISIN Code -
Under CPF Investment Scheme (CPFIS) No
指数成分股
数据延迟。最后一次更新26 Feb 2021 00:22.
数据提供商

未来大事

* 美国时间.

Earnings

释放日期 31 Mar 2021
查看所有活动

关于 CELSION CORPORATION

Celsion Corporation is an oncology drug development company focused on the development of treatments for those suffering with difficult to treat forms of cancer. As of December 31, 2011, the Company's product ThermoDox is being evaluated in a Phase III clinical trial for primary liver cancer (the HEAT study), a Phase II clinical trial for colorectal liver metastasis (CRLM) and a Phase II clinical trial for recurrent chest wall breast cancer. ThermoDox is a liposomal encapsulation of doxorubicin, an approved and frequently used oncology drug for the treatment of a range of cancers. Localized heat at mild hyperthermia temperatures releases the encapsulated doxorubicin from the liposome enabling high concentrations of doxorubicin to be deposited preferentially in and around the targeted tumor. In June 2014, it acquired all of the assets of EGEN Inc.

Loading Chart...